Literature DB >> 23504588

The role of natural killer T cells in B cell malignancies.

Ghasem Ghalamfarsa1, Abolghasem Hadinia, Mehdi Yousefi, Farhad Jadidi-Niaragh.   

Abstract

Little is known regarding the precise role of different subsets of natural killer T (NKT) cells in the immunopathogenesis of cancer diseases, particularly hematopoietic malignancies. Although it is well known that NKT cells counteract tumor immunity, conflicting reports on the role of NKT cells in hematopoietic malignancies support more investigations to clarify the interactions between NKT cells and the tumor. Among the hematopoietic malignancies, B cell malignancies derive from different stages of B cell maturation in which T cells play a pivotal role. There is evidence which implies the protective role of some subsets of NKT cells in solid cancers as well as B cell malignancies. In this review, we will discuss recent advances about the immunobiology of NKT cells and their precise role in the immunopathogenesis and treatment of different B cell malignancies.

Entities:  

Mesh：

Year:  2013        PMID： 23504588     DOI： 10.1007/s13277-013-0743-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  108 in total

Review 1.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

2.  Commitment toward the natural T (iNKT) cell lineage occurs at the CD4+8+ stage of thymic ontogeny.

Authors:  Jelena S Bezbradica; Timothy Hill; Aleksandar K Stanic; Luc Van Kaer; Sebastian Joyce
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-25       Impact factor: 11.205

Review 3.  CD1 antigen presentation: how it works.

Authors:  Duarte C Barral; Michael B Brenner
Journal:  Nat Rev Immunol       Date:  2007-12       Impact factor: 53.106

4.  Regulation of NKT cell development by SAP, the protein defective in XLP.

Authors:  Kim E Nichols; Jamie Hom; Shun-You Gong; Arupa Ganguly; Cindy S Ma; Jennifer L Cannons; Stuart G Tangye; Pamela L Schwartzberg; Gary A Koretzky; Paul L Stein
Journal:  Nat Med       Date:  2005-02-13       Impact factor: 53.440

Review 5.  Raising the NKT cell family.

Authors:  Dale I Godfrey; Sanda Stankovic; Alan G Baxter
Journal:  Nat Immunol       Date:  2010-02-07       Impact factor: 25.606

Review 6.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

7.  NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.

Authors:  Stephen R Mattarollo; Alison C West; Kim Steegh; Helene Duret; Christophe Paget; Ben Martin; Geoffrey M Matthews; Jake Shortt; Marta Chesi; P Leif Bergsagel; Michael Bots; Johannes Zuber; Scott W Lowe; Ricky W Johnstone; Mark J Smyth
Journal:  Blood       Date:  2012-08-28       Impact factor: 22.113

8.  TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells.

Authors:  M Nieda; A Nicol; Y Koezuka; A Kikuchi; N Lapteva; Y Tanaka; K Tokunaga; K Suzuki; N Kayagaki; H Yagita; H Hirai; T Juji
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

9.  Tumour-loaded α-type 1-polarized dendritic cells from patients with chronic lymphocytic leukaemia produce a superior NK-, NKT- and CD8+ T cell-attracting chemokine profile.

Authors:  Karin Gustafsson; Katarina Junevik; Olle Werlenius; Sandra Holmgren; Alex Karlsson-Parra; Per-Ola Andersson
Journal:  Scand J Immunol       Date:  2011-09       Impact factor: 3.487

10.  Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection.

Authors:  Lucy Golden-Mason; Nicole Castelblanco; Cliona O'Farrelly; Hugo R Rosen
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103
View more
  9 in total

1.  Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.

Authors:  Rupali Das; Peng Guan; Susan J Wiener; Nishant P Patel; Trevor G Gohl; Elizabeth Evans; Maurice Zauderer; Kim E Nichols
Journal:  Blood Adv       Date:  2019-03-12

2.  Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles.

Authors:  Farhad Jadidi-Niaragh; Fatemeh Atyabi; Ali Rastegari; Esmail Mollarazi; Melika Kiani; Alireza Razavi; Mehdi Yousefi; Nasim Kheshtchin; Hadi Hassannia; Jamshid Hadjati; Fazel Shokri
Journal:  Tumour Biol       Date:  2016-01-05

Review 3.  Myeloid-derived suppressor cells in B cell malignancies.

Authors:  Yaghoub Yazdani; Mousa Mohammadnia-Afrouzi; Mehdi Yousefi; Enayat Anvari; Ghasem Ghalamfarsa; Hadi Hasannia; Sanam Sadreddini; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2015-09-02

4.  Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.

Authors:  A C Chan; P Neeson; E Leeansyah; K Tainton; H Quach; H M Prince; S J Harrison; D I Godfrey; D Ritchie; S P Berzins
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

5.  Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas.

Authors:  Changchun Fan; Xuechun Zhao; Zhixing Xu
Journal:  Tumour Biol       Date:  2014-09-18

6.  NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.

Authors:  Takumi Kobayashi; Brianna L Doff; Rory C Rearden; Graham R Leggatt; Stephen R Mattarollo
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

7.  NKT Cell Responses to B Cell Lymphoma.

Authors:  Junxin Li; Wenji Sun; Priyanka B Subrahmanyam; Carly Page; Kenisha M Younger; Irina V Tiper; Matthew Frieman; Amy S Kimball; Tonya J Webb
Journal:  Med Sci (Basel)       Date:  2014-06-01

Review 8.  The molecular biology and therapeutic potential of Nrf2 in leukemia.

Authors:  Atefeh Khodakarami; Sara Adibfar; Vahid Karpisheh; Shiva Abolhasani; Pooya Jalali; Hamed Mohammadi; Jamshid Gholizadeh Navashenaq; Mohammad Hojjat-Farsangi; Farhad Jadidi-Niaragh
Journal:  Cancer Cell Int       Date:  2022-07-29       Impact factor: 6.429

9.  Anticancer Potential of Xanthohumol and Isoxanthohumol Loaded into SBA-15 Mesoporous Silica Particles against B16F10 Melanoma Cells.

Authors:  Tamara Krajnović; Nebojša Đ Pantelić; Katharina Wolf; Thomas Eichhorn; Danijela Maksimović-Ivanić; Sanja Mijatović; Ludger A Wessjohann; Goran N Kaluđerović
Journal:  Materials (Basel)       Date:  2022-07-19       Impact factor: 3.748
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.